ZYME

#1967
Zymeworks Inc.
27.1571 USD
+3.77%
版块: 医疗保健
基础: USD
利润货币: USD
日范围
27.1500
27.1900
年范围
16.0034
28.4900
日变化
+3.77%
每月变动
+17.21%
6个月变化
+53.08%
年变化
+53.08%
前一天收盘价
26.1700
开盘价
27.1500
买价
卖价
最低价
27.1500
High
27.1900
交易量
4
展开完整图表

Financials

概览 声明 统计
每季度 年度
  • Market Capitalization 2.0028 B
  • Employee 264
  • Founded 2003
  • CEO Kenneth Galbraith
  • Website www.zymeworks.com
  • Headquarter Delaware, United States
  • FIGI BBG019XSYC89
  • Industry Technology
总收入
净利润
每股基本收益（基本 EPS）
总债务
自由现金流
现金及现金等价物
市盈率
-24.38
市销率
18.74

Zymeworks Inc

Zymeworks Inc. is a publicly held biotechnology company based in Vancouver, British Columbia, that develops protein therapeutics for the treatment of cancer as well as for autoimmune and inflammatory diseases. The products are based upon the company's molecular modeling software for optimizing protein structure. In 2014, Zymeworks raised $44 million across various funding rounds according to PitchBook, placing it among the top 10 HealthTech businesses in the world to raise the most capital that year. In May 2017, Zymeworks held an IPO on the Toronto Stock Exchange, raising $59 million. This was the largest Canadian biotech IPO in more than a decade. By alphabetical order, Zymeworks is the last company on the Toronto Stock Exchange. In May 2019, Zymeworks announced that GSK has expanded its 2016 licensing and collaboration agreement for the research, development and commercialization of bispecific antibodies across multiple disease areas. The extended agreement has meant that GSK can have access to Zymeworks' heavy-light chain pairing technology, which enables the development of bispecific and multifunctional therapeutics.

新闻